|
news on trastuzumab-dm1/ itsa GO
Genentech announced it made a Phase III "go" decision to study Trastuzumab-DM1 (T-DM1) as a potential second-line treatment for HER2-positive metastatic breast cancer.
In the third quarter of 2008, the company initiated enrollment in two Phase II studies of T-DM1 as potential first-line and third-line treatments for patients with HER2-positive metastatic breast cancer.
run to live
|
Threaded Mode